✦ LIBER ✦

Digoxin bioavailability: Evaluation of a generic tablet and proposed FDA guidelines

✍ Scribed by William G. Kramer; Albert J. Kolibash; Mohinder S. Bathala; James A. Visconti; Richard P. Lewis; Richard H. Reuning

Publisher: John Wiley and Sons
Year: 1977
Tongue: English
Weight: 392 KB
Volume: 66
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.2600661216

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bioavailability of generic ritonavir and

Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model

✍ Kevin W. Garren; Sibtain Rahim; Kennan Marsh; John B. Morris 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

In this study, we explored the bioavailability in dogs and chemical potency of generic ritonavir and lopinavir/ritonavir tablet products manufactured by various pharmaceutical companies. Chemical potency of the products was examined by HPLC quantitation of ritonavir and lopinavir. Using a dog model,

Bioavailability of generic ritonavir and

Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model

✍ Kevin W. Garren; Sibtain Rahim; Kennan Marsh; John B. Morris 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 1 views

We would like to respond to the two Letters to the Editor that have been submitted in response to our manuscript reporting on the relative bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in dogs. Both Letters criticize the dog model used in our studies, suggesting that

Re: Acknowledgement of human bioequivale

Re: Acknowledgement of human bioequivalency of matrix's lopinavir–ritonavir formulation to Kaletra®, comment to article on bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.

✍ Russell J. Rackley 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB